pd 153035 and gefitinib

pd 153035 has been researched along with gefitinib in 23 studies

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (34.78)29.6817
2010's15 (65.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheung, K; Dushin, RG; Floyd, MB; Fraser, HL; Ingalls, CL; Loganzo, F; Nittoli, T; Ravi, MR; Tan, X; Wissner, A1
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Chen, Z; Lou, Y; Yu, Y; Zhang, Y1
Depreux, P; Farce, A; Garofalo, A; Goossens, L; Lemoine, A; Ravez, S; Six, P1
Gallus, J; Juvale, K; Wiese, M1
Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA1
Hu, L; Li, Z; Liu, P; Pan, Z; Qin, X; Yang, L; Zeng, C1
Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q1
Das, D; Hong, J1
Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ1
Asquith, CRM; Treiber, DK; Zuercher, WJ1
Asquith, CRM; Crona, DJ; Fleck, N; Grundner, C; Torrice, CD; Zuercher, WJ1
Klar, U; Lichtner, RB; Menrad, A; Schneider, MR; Sommer, A1
Chang, CM; Li, B; McKenna, WG; Shu, HK; Yuan, M1
Chansel, D; Chatziantoniou, C; Dussaule, JC; Flamant, M; François, H; Placier, S; Tharaux, PL1
Gaiger, A; Grunt, TW; Kainz, B; Köhler, G; Puckmair, K; Rünzler, D; Tomek, K; Wagner, R; Zielinski, CC1
Breza, N; Keri, G; Orfi, L; Petak, I; Pinter, F; Robert, K; Schwab, R; Varkondi, E1
Muro, Y; Shimoyama, Y; Sugiura, K; Tomita, Y; Yamaki, M1
Haramoto, M; Horibe, T; Kawakami, K; Kohno, M; Matsuzaki, K; Nakajima, O; Ohara, K; Yano, Y1
Pick, A; Wiese, M1
Matsuo, K; Takada, Y1
Eda, T; Iwakura, Y; Mizuno, M; Nagata, K; Namba, H; Nawa, H; Okubo, T; Shibuya, M; Sotoyama, H; Wang, R1
Liu, W; Qin, ZP; Xing, RC; Yao, RC; Zheng, J; Zheng, WH1

Reviews

2 review(s) available for pd 153035 and gefitinib

ArticleYear
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
    Bioorganic & medicinal chemistry, 2019, 02-01, Volume: 27, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines

2019
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
    European journal of medicinal chemistry, 2019, May-15, Volume: 170

    Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2019

Other Studies

21 other study(ies) available for pd 153035 and gefitinib

ArticleYear
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Bioorganic & medicinal chemistry, 2007, Jun-01, Volume: 15, Issue:11

    Topics: Adenosine Triphosphate; Binding Sites; Biological Assay; Cells, Cultured; ErbB Receptors; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Structure; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-2

2007
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:1

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Female; Humans; Male; Quinazolines

2009
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.
    Bioorganic & medicinal chemistry letters, 2011, Apr-01, Volume: 21, Issue:7

    Topics: Cell Line, Tumor; Cell Proliferation; Humans; Models, Molecular; Quinazolines; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2

2011
Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
    Bioorganic & medicinal chemistry, 2013, Dec-15, Volume: 21, Issue:24

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dogs; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasm Proteins; Quinazolines; Structure-Activity Relationship

2013
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
    European journal of medicinal chemistry, 2015, Sep-18, Volume: 102

    Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship

2015
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
    Bioorganic & medicinal chemistry, 2016, 07-01, Volume: 24, Issue:13

    Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Drug Discovery; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Molecular Structure; Mutation; Protein Binding; Quinazolines

2016
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
    Journal of medicinal chemistry, 2019, 05-09, Volume: 62, Issue:9

    Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines

2019
Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).
    Bioorganic & medicinal chemistry letters, 2019, 07-15, Volume: 29, Issue:14

    Topics: Cyclin G; Humans; Protein Kinase Inhibitors; Quinolines

2019
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
    Bioorganic & medicinal chemistry letters, 2019, 09-15, Volume: 29, Issue:18

    Topics: Aniline Compounds; Antitubercular Agents; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Quinazolines; Quinolines; Structure-Activity Relationship

2019
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Cancer research, 2001, Aug-01, Volume: 61, Issue:15

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Kinetics; Ligands; Lung Neoplasms; Mammary Neoplasms, Experimental; Phthalimides; Quinazolines; Rats; Signal Transduction; Tumor Cells, Cultured

2001
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Cancer research, 2003, Nov-01, Volume: 63, Issue:21

    Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glioma; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Trans-Activators; Tumor Suppressor Proteins

2003
Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:7

    Topics: Animals; Capillaries; Collagen; Collagen Type I; Creatinine; Endothelin-1; ErbB Receptors; Fibrosis; Gefitinib; Gene Expression Regulation; Genes, Reporter; Glomerulosclerosis, Focal Segmental; Hypertension; Ischemia; Kidney; Kidney Cortex; Kidney Diseases; Kidney Glomerulus; Male; MAP Kinase Signaling System; Mice; Mice, Transgenic; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphorylation; Promoter Regions, Genetic; Protein Processing, Post-Translational; Proteinuria; Quinazolines; Rats; Rats, Sprague-Dawley

2004
Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.
    Journal of cellular physiology, 2007, Volume: 211, Issue:3

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; CpG Islands; DNA Methylation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Quinazolines; Receptors, Retinoic Acid; RNA Processing, Post-Transcriptional; Transcription, Genetic; Tyrphostins; Up-Regulation

2007
Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.
    Journal of receptor and signal transduction research, 2008, Volume: 28, Issue:3

    Topics: Aminoquinolines; Aniline Compounds; Biological Assay; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Inhibitory Concentration 50; Morpholines; Mutant Proteins; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tyrphostins

2008
Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
    Experimental dermatology, 2010, Volume: 19, Issue:8

    Topics: Acneiform Eruptions; Adolescent; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Line; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-1; Keratinocytes; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptors, Interleukin-1; Receptors, Interleukin-1 Type II; RNA, Messenger; Signal Transduction

2010
A novel hybrid peptide targeting EGFR-expressing cancers.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:5

    Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Mutant Chimeric Proteins; Neoplasm Transplantation; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous

2011
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    ChemMedChem, 2012, Volume: 7, Issue:4

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Cell Line; Cetuximab; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Morpholines; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Tyrphostins

2012
Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
    The Keio journal of medicine, 2012, Volume: 61, Issue:4

    Topics: Animals; Antineoplastic Agents; Chemokine CCL2; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Lipopolysaccharides; Lung Diseases, Interstitial; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Tumor Necrosis Factor-alpha

2012
ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions.
    Translational psychiatry, 2013, Apr-30, Volume: 3

    Topics: Animals; Antipsychotic Agents; Brain Chemistry; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Male; Motor Activity; Quinazolines; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia; Schizophrenic Psychology

2013
Relevance of E-cadherin expression to EGFR-TKI molecular targeted therapy sensitivity/resistance and its clinical significance.
    Genetics and molecular research : GMR, 2015, May-29, Volume: 14, Issue:2

    Topics: Breast Neoplasms; Cadherins; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Signal Transduction

2015